- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 203732, 11 pages
In Vivo Study on the Pharmacological Interactions between a Chinese Herbal Formula ELP and Antiresorptive Drugs to Counteract Osteoporosis
1Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
2State Key Laboratory of Phytochemistry and Plant Resources in West China, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
3Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
4Jockey Club Centre for Osteoporosis Care and Control, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
5School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
6School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong
Received 12 July 2012; Revised 3 September 2012; Accepted 12 September 2012
Academic Editor: Norazlina Mohamed
Copyright © 2012 Chun-Hay Ko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. Dennison, M. A. Mohamed, and C. Cooper, “Epidemiology of osteoporosis,” Rheumatic Disease Clinics of North America, vol. 32, no. 4, pp. 617–629, 2006.
- L. S. Lim, L. J. Hoeksema, and K. Sherin, “Screening for osteoporosis in the adult U.S. population. ACPM position statement on preventive practice,” American Journal of Preventive Medicine, vol. 36, no. 4, pp. 366–375, 2009.
- W. D. Leslie and J. T. Schousboe, “A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world,” Current Osteoporosis Reports, vol. 9, no. 3, pp. 129–140, 2011.
- International Osteoporosis Foundation, Epidemiology, http://www.iofbonehealth.org/epidemiology.
- B. Gullberg, O. Johnell, and J. A. Kanis, “World-wide projections for hip fracture,” Osteoporosis International, vol. 7, no. 5, pp. 407–413, 1997.
- E. S. Siris, P. L. Selby, K. G. Saag, F. Borgström, R. M. C. Herings, and S. L. Silverman, “Impact of osteoporosis treatment adherence on fracture rates in North America and Europe,” American Journal of Medicine, vol. 122, no. 2, pp. S3–S13, 2009.
- D. G. Pendrys and S. L. Silverman, “Osteonecrosis of the jaws and bisphosphonates,” Current Osteoporosis Reports, vol. 6, no. 1, pp. 31–38, 2008.
- K. Briot, F. Trémollières, T. Thomas, and C. Roux, “How long should patients take medications for postmenopausal osteoporosis?” Joint Bone Spine, vol. 74, no. 1, pp. 24–31, 2007.
- W. S. Siu, H. L. Wong, C. P. Lau, et al., “Theeffects of an antiosteoporosis herbal formula containing Epimedii Herba, Ligustri Lucidi Fructus and Psoraleae Fructus on density and structure of rat long bones under tail-suspension, and its mechanisms ofaction,” Phytotherapy Research. In press.
- Y. Sun, S. M. Y. Lee, Y. M. Wong et al., “Dosing effects of an antiosteoporosis herbal formula—a preclinical investigation using a rat model,” Phytotherapy Research, vol. 22, no. 2, pp. 267–273, 2008.
- P. C. Leung, K. F. Cheng, and Y. H. Chan, “An innovative herbal product for the prevention of osteoporosis,” Chinese Journal of Integrative Medicine, vol. 17, no. 10, pp. 744–749, 2011.
- M. S. Wong, S. K. Mok, W. F. Chen et al., “Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells,” British Journal of Pharmacology, vol. 159, no. 4, pp. 939–949, 2010.
- J. Zhao, S. Ohba, Y. Komiyama, M. Shinkai, U. I. Chung, and T. Nagamune, “Icariin: a potential osteoinductive compound for bone tissue engineering,” Tissue Engineering A, vol. 16, no. 1, pp. 233–243, 2010.
- C. H. Ko, K. M. Lau, W. Y. Choy, and P. C. Leung, “Effects of tea catechins, epigallocatechin, gallocatechin, and gallocatechin gallate, on bone metabolism,” Journal of Agricultural and Food Chemistry, vol. 57, no. 16, pp. 7293–7297, 2009.
- Chinese Pharmacopeia Commission, Chinese Pharmacopeia Commission, Pharmacopoeia of the People's Republic of China, Chinese Medical Science and Technology Press, Beijing, China, 2010.
- Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers, U.S. Food and Drug Administration, Rockville, Md, USA, 2005.
- J. A. Guy, M. Shea, C. P. Peter, R. Morrissey, and W. C. Hayes, “Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties,” Calcified Tissue International, vol. 53, no. 4, pp. 283–288, 1993.
- L. J. Black, M. Sato, E. R. Rowley et al., “Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats,” Journal of Clinical Investigation, vol. 93, no. 1, pp. 63–69, 1994.
- M. Sato, J. Kim, L. L. Short, C. W. Slemenda, and H. U. Bryant, “Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 272, no. 3, pp. 1252–1259, 1995.
- S. Anumula, S. L. Wehrli, J. Magland, A. C. Wright, and F. W. Wehrli, “Ultra-short echo-time MRI detects changes in bone mineralization and water content in OVX rat bone in response to alendronate treatment,” Bone, vol. 46, no. 5, pp. 1391–1399, 2010.
- C. A. Inderjeeth, K. Chan, K. Kwan, and M. Lai, “Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments,” Journal of Bone and Mineral Metabolism, vol. 30, no. 5, pp. 493–503, 2012.
- R. B. Hopkins, R. Goeree, E. Pullenayegum et al., “The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women,” BMC Musculoskeletal Disorders, vol. 12, article 209, 2011.
- W. S. Siu, L. Qin, and K. S. Leung, “pQCT bone strength index may serve as a better predictor than bone mineral density for long bone breaking strength,” Journal of Bone and Mineral Metabolism, vol. 21, no. 5, pp. 316–322, 2003.
- P. G. Bradford, K. V. Gerace, R. L. Roland, and B. G. Chrzan, “Estrogen regulation of apoptosis in osteoblasts,” Physiology and Behavior, vol. 99, no. 2, pp. 181–185, 2010.
- A. Zallone, “Direct and indirect estrogen actions on osteoblasts and osteoclasts,” Annals of the New York Academy of Sciences, vol. 1068, no. 1, pp. 173–179, 2006.
- L. J. Dominguez, G. Di Bella, M. Belvedere, and M. Barbagallo, “Physiology of the aging bone and mechanisms of action of bisphosphonates,” Biogerontology, vol. 12, no. 5, pp. 397–408, 2011.
- A. Taranta, M. Brama, A. Teti et al., “The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro,” Bone, vol. 30, no. 2, pp. 368–376, 2002.
- H. Michael, P. L. Härkönen, L. Kangas, H. K. Väänänen, and T. A. Hentunen, “Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro,” British Journal of Pharmacology, vol. 151, no. 3, pp. 384–395, 2007.